skip to Global Navigation Bar skip to main content


homeHome > R&D > Pipeline

 Pipeline

Daewoong Pharmaceutical’s R&D Division

wil focus its skills and resources on chronic and intractable diseases that are in high demand from the market and such areas of interest as improvement of the quality of life and provide patients with innovative drugs (chemical or bio), incrementally modified drugs, and new botanical treatments.

New Chemical Entity

New Chemical Entity table
Project MOA Description Status(KR)
R Pre P1 P2 P3 M*
DWP14012 APA(Reversible) Gastrointestinal Disease
DWP16001 SGLT-2 inhibitor Diabetes
DWP17011 PRS Inhibitor Fibrotic disease
DWJ208 Ion channel blocker Neuropathic pain, cancer pain
DWJ212 Dual Target Inhibitor Autoimmune disease (RA)
DWJ213 Dual Target Inhibitor Autoimmune disease (RA)

Biologics

Biologics table
Project MOA Description Status(KR)
R Pre P1 P2 P3 M*
DWP457 Long acting insulin Diabetes
DWJ815 Undisclosed Protein Osteoarthritis
DWSR-001 Stem Cell Osteoarthritis, Alzheimer’s
Disease, Acue Liver Failure